Compare Albemarle Corp. (ALB) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs Davita Inc — how do they compare? Albemarle Corp. trades at $130.13 (market cap $15.48B), while Davita Inc trades at $178.34 (market cap $11.72B). The key difference: Albemarle Corp. is the larger of the two by market cap, and Albemarle Corp. pays a 1.25% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| ALB | DVA | |
|---|---|---|
Market Cap | $15.48B | $11.72B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $240.96 |
52-Week Low | $72.58 | $103.87 |
Enterprise Value | $17.96B | $24.44B |
Dividend Yield | 1.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) trades at $131.11, up 4.54% today, with a bullish technical signal and strong Q2 2026 earnings beating estimates. The stock shows improved cash flow and lithium demand strength, though valuation metrics like a P/E of 485.59 indicate high expectations. Recent news highlights earnings growth and dividend stability, with support at $127 and resistance at $134.
Outlook is cautiously optimistic with analyst consensus target of $184.50, but risks include volatile lithium prices and high valuation. Investment opportunity lies in sustained demand for energy storage, balanced by margin pressures and debt levels.
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
